Ocular Hypertension Treatment Market to Grow with a CAGR of 3.82% through 2028
Rising
advancements
in treatment modalities are expected to drive the Global Ocular Hypertension
Treatment Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Ocular
Hypertension Treatment Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Ocular
Hypertension Treatment Market stood at USD 3.67 billion in 2022 and is
anticipated to grow with a CAGR of 3.82% in the forecast period, 2024-2028. The
Global Ocular Hypertension Treatment Market is experiencing remarkable growth,
driven by a confluence of factors that are reshaping the landscape of ocular
healthcare. Ocular hypertension, characterized by elevated intraocular
pressure, poses a significant risk factor for glaucoma, a leading cause of
irreversible blindness worldwide.
One
of the primary drivers behind the growth of the ocular hypertension treatment
market is the aging global population. As individuals age, the risk of
developing ocular hypertension and subsequent glaucoma increases. The elderly
are particularly vulnerable to these conditions due to changes in the eye's
drainage system, which can impede the flow of aqueous humor and lead to
elevated intraocular pressure. Changing lifestyle patterns and the prevalence
of digital devices are contributing significantly to the rise in ocular
hypertension cases. Prolonged screen time, extensive use of smartphones and
computers, and increased exposure to artificial lighting can strain the eyes,
potentially leading to ocular hypertension. As individuals of all ages spend
more time engaged with screens, the demand for ocular hypertension treatments,
including eye drops and preventive measures, has surged. Lifestyle factors are
thus acting as a driving force behind the market's expansion.
The ocular hypertension treatment market has witnessed
a notable transformation with the introduction of innovative therapeutic
options. While eye drops and oral medications have traditionally been the
mainstay of treatment, advancements in surgical techniques have expanded the
treatment landscape. Micro-invasive glaucoma surgery (MIGS) is a prime example
of this evolution. MIGS procedures are less invasive than traditional glaucoma
surgeries and offer a more effective approach to managing intraocular pressure.
These minimally invasive techniques have gained popularity among both patients
and clinicians, enhancing the market's growth prospects.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Ocular
Hypertension Treatment Market.”
Rising awareness about the importance of early
detection and treatment of ocular hypertension is a pivotal driver behind
market growth. Ophthalmologists, patient advocacy groups, and healthcare
organizations are actively involved in educational campaigns to highlight the
risks associated with untreated ocular hypertension. Early diagnosis and
intervention not only prevent vision loss but also reduce the economic burden
of treating advanced glaucoma. As more people become aware of the potential
consequences of ocular hypertension, they are seeking timely treatment and
contributing to market expansion.
The Global Ocular Hypertension Treatment Market is
segmented into Type, Route of Administration, Distribution Channel, Regional
Distribution, And Company.
Based on the Type, the Glaucoma emerged
as the dominant segment in the global market for Global Ocular Hypertension
Treatment Market in 2022. Intraocular hypertension refers to elevated
intraocular pressure, which is a significant risk factor for the development of
glaucoma. Not everyone with ocular hypertension will develop glaucoma, but a
substantial proportion of glaucoma cases stem from untreated or inadequately
managed intraocular hypertension. Therefore, the demand for ocular hypertension
treatment is intrinsically linked to the prevention and management of glaucoma,
making glaucoma the primary driver of demand within the market. Glaucoma is a
leading cause of irreversible blindness globally, and it affects a substantial
number of individuals. According to the World Health Organization (WHO),
approximately 3% of the world's population aged 40 to 80 years has some form of
glaucoma. This high prevalence of glaucoma contributes significantly to the
demand for ocular hypertension treatments, as a considerable portion of those
affected by glaucoma initially presented with intraocular hypertension.
Early detection and treatment of
intraocular hypertension are critical in preventing the progression to glaucoma
and preserving vision. As awareness of the link between intraocular
hypertension and glaucoma grows, more individuals seek timely intervention to
manage their elevated intraocular pressure effectively. This emphasis on early
detection and treatment underscores the demand for ocular hypertension
treatments, especially in cases where glaucoma can be prevented or delayed.
Based on the Distribution Channel, the
Retail Pharmacy segment emerged as the dominant player in the global market for
Global Ocular Hypertension Treatment Market in 2022. Retail pharmacies are
widespread and easily accessible, offering a physical presence in local
communities and healthcare facilities. Patients with ocular hypertension can
visit these pharmacies conveniently to purchase prescribed eye drops or
medications, making it a preferred choice for many individuals, especially
older patients who may be less familiar with online options. Retail pharmacies
provide the opportunity for patients to consult with pharmacists, who can offer
guidance and answer questions about ocular hypertension medications.
Patients can receive personalized advice
on proper usage, potential side effects, and interactions with other
medications, which enhances treatment adherence and safety. Retail pharmacies
offer immediate access to medications, allowing patients to begin treatment
promptly after receiving their prescriptions. This quick turnaround is crucial
in managing conditions like ocular hypertension, where timely treatment can
prevent progression to glaucoma and vision loss.
North America emerged as the dominant
player in the global Ocular Hypertension Treatment Market in 2022, holding the
largest market share. North America boasts a highly developed and advanced
healthcare infrastructure, comprising state-of-the-art medical facilities,
well-trained healthcare professionals, and cutting-edge diagnostic and
treatment technologies. This infrastructure supports the early diagnosis and
effective management of ocular hypertension, contributing to the region's
dominant position in the market. North America has a significant prevalence of
ocular hypertension and glaucoma cases, partly due to an aging population. The
demographic shift toward an older population is contributing to a larger
patient pool in need of ocular hypertension treatments, thereby driving market
growth. The region
places a strong emphasis on healthcare awareness and screening programs.
Increased public awareness of ocular health, regular eye check-ups, and the
link between ocular hypertension and glaucoma have led to early detection and
treatment, further consolidating North America's dominant market position.
Major companies operating in Global Ocular
Hypertension Treatment Market are:
- Angelini Spa
- Laboratorios Sophia
- Neurim Pharmaceuticals Ltd
- Nicox SA
- Novartis AG.
- Aerie Pharmaceuticals, Inc.
- Abbvie, Inc
- Angelini Pharma S.p.a.
- Chong Kun Dang pharmaceutical Corp
- Lee Pharma Ltd
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Ocular Hypertension Treatment Market is poised for substantial growth in the
coming years. This optimism is fueled by a convergence of factors that are
reshaping the landscape of ocular healthcare. Rising awareness about ocular
health, coupled with increased access to advanced diagnostic tools, is expected
to lead to early detection and intervention for ocular hypertension, preventing
its progression to glaucoma. Pharmaceutical innovations, including more
patient-friendly eye drops and sustained-release medications, are improving
treatment adherence and efficacy. Minimally invasive surgical techniques, such
as Micro-Invasive Glaucoma Surgery (MIGS), are gaining prominence for their
superior safety profiles and quicker recovery times. Additionally, the
expansion of telemedicine and remote monitoring is enhancing accessibility to
ocular care, particularly in underserved regions.” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Ocular Hypertension Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Type (Intraocular Hypertension, Glaucoma), By Route Of Administration (Oral,
Parenteral, Other), By Distribution Channel (Retail Pharmacy, Online Pharmacy,
Other) By Region and Competition”, has evaluated the future growth potential of Global
Ocular Hypertension Treatment Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global Ocular Hypertension Treatment Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com